ArticleCancers2020

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation.

Hua Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.